Edition:
United States

Cidara Therapeutics Inc (CDTX.OQ)

CDTX.OQ on NASDAQ Stock Exchange Global Market

6.60USD
23 Feb 2018
Change (% chg)

$-0.10 (-1.49%)
Prev Close
$6.70
Open
$6.75
Day's High
$6.75
Day's Low
$6.53
Volume
21,579
Avg. Vol
17,866
52-wk High
$8.80
52-wk Low
$5.60

Chart for

About

Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio... (more)

Overall

Beta: --
Market Cap(Mil.): $132.56
Shares Outstanding(Mil.): 20.24
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 195.87 16.59
EPS (TTM): -- -- --
ROI: -- -0.71 35.07
ROE: -- -3.37 17.79

BRIEF-Cidara Therapeutics Completes Enrollment in Phase 2 Strive Trial for Antifungal Rezafungin

* CIDARA THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2 STRIVE TRIAL EVALUATING NOVEL ANTIFUNGAL REZAFUNGIN (CD101 IV) IN INVASIVE FUNGAL INFECTIONS Source text for Eikon: Further company coverage:

Nov 28 2017

BRIEF-Cidara Therapeutics announces pricing of $20 mln private placement

* Cidara Therapeutics announces pricing of $20 million private placement of common stock

Oct 19 2017

Earnings vs. Estimates